Palatin Technologies (PTN) Non-Current Deffered Revenue (2011 - 2018)
Palatin Technologies' (PTN) quarterly Non-Current Deffered Revenue came in at $500000.0 in Q2 2018, little changed on a QoQ basis from $500000.0 in Q1 2018.
Palatin Technologies (PTN) Non-Current Deffered Revenue (2011 - 2018) Analysis & Trends
Palatin Technologies (PTN) has 5 years of Non-Current Deffered Revenue data on file, last reported at $500000.0 in Q2 2018.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $500000.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $500000.0 (changed N/A YoY) and the FY2018 annual result came in at $500000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue steadied at $500000.0 in Q2 2018, from $500000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $500000.0 in Q4 2017 to a low of $500000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 500,000.00 |
| Mar 31, 2018 | 500,000.00 |
| Dec 31, 2017 | 500,000.00 |
| Mar 31, 2013 | 44,764.00 |
| Dec 31, 2012 | 54,068.00 |
| Sep 30, 2012 | 63,372.00 |
| Jun 30, 2012 | 72,677.00 |
| Mar 31, 2012 | 81,981.00 |
| Dec 31, 2011 | 91,285.00 |
| Sep 30, 2011 | 100,589.00 |
| Jun 30, 2011 | 132,855.00 |